23 NOWE BADANIA KLINICZNE

W dniu 1.08.2019 r. sfinalizowano aktualizację listy badań klinicznych w poszczególnych ankietach ewaluacyjnych, dodając oraz usuwając następujące badania: 
Atopowe zapalenie skóry:
Dodano: 
- CrisaboroleAtD (A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD)
JADE EXTEND (Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis)
TezapeAtD (A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis)
NemoliAtD (Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis)
Przewlekła choroba nerek:
Dodano: 
SAPPHIRE (A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia)
FERUXIDA (A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD))
VALOR-CKD (Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis)
PRO2TECT (Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD))
PRO2TECT.2 (Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD))
KALM-2 (CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus)
Reumatoidalne zapalenie stawów: 
Dodano: 
- ABBV105/599 (A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib.)
RA-BRIDGE (A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis)
Usunięto:
FINCH IV (Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis)
EVO (Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis)
Stwardnienie rozsiane:
Dodano: 
OfatSM (Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS)
Usunięto:
EVOLVE-MS-2 (A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis)
Toczeń rumieniowaty układowy:
Dodano: 
- 
LT  BMS-986165 SLE (Long-Term Safety and Efficacy Study of BMS-986165 in Participants With Systemic Lupus Erythematosus)
ABBV-105&Upa (A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus)
VAY736 & CFZ533 SLE (Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients)
BMS-986165 LupNephr (An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis)
Usunięto:
LILAC (Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus)
Wrzodziejące zapalenie jelita grubego: 
Dodano:
ABX464 2b (Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis)
BMS-986165 UC (Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis (UC))
RHEA (Efficacy & Safety of TD-1473 in Ulcerative Colitis)
TD-1473 UC (Efficacy & Safety of TD-1473 in Ulcerative Colitis)
SHR0302 UC (A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis)
ST-0529 UC (A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis)
Usunięto:
- AiPSwMtSUC (Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis)
EtroPedUC (A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease)